Compare Inovio Pharmaceuticals Inc (INO) vs Packaging Corporation of America (PKG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Packaging Corporation of America — how do they compare? Inovio Pharmaceuticals Inc trades at $1.1 (market cap $119.42M), while Packaging Corporation of America trades at $231.22 (market cap $20.25B). The key difference: Packaging Corporation of America is far larger — about 169.6× Inovio Pharmaceuticals Inc's market cap, and Packaging Corporation of America pays a 2.64% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and Packaging Corporation of America for 45 Days on average.
| INO | PKG | |
|---|---|---|
Market Cap | $119.42M | $20.25B |
Volume | 2,789,649 | 491,102 |
Sector | Health | Consumer Cyclical |
52-Week High | $2.65 | $257.43 |
52-Week Low | $0.66 | $191.68 |
Typical Hold Time | 43 Days | 45 Days |
Enterprise Value | $90.75M | $24.06B |
Dividend Yield | — | 2.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.09, down 3.54% on the day, with a bearish technical signal driven by moving averages. The company reported a net loss of $84.95 million in 2025 on minimal revenue of $65,340, with negative profitability metrics, but has beaten EPS estimates in recent quarters. Key near-term catalyst is the FDA's October 30, 2026 PDUFA date for INO-3107.
The investment case hinges on regulatory approval of INO-3107, with a consensus price target of $2.75 implying significant upside. However, extreme financial losses, high cash burn, and dependence on dilutive financing pose substantial risks. Analyst sentiment is cautiously optimistic but reflects high uncertainty.
Packaging Corporation of America (PKG) trades at $227.25, down 1.08% with bearish technical signals despite recent earnings beats. The company maintains solid fundamentals with $9.5B revenue projection for 2026 and 7.25% net margin, though facing margin compression from cost pressures. Recent institutional buying by BlackRock and Bank of New York Mellon contrasts with mixed analyst ratings.
PKG offers steady packaging demand exposure but faces headwinds from rising input costs and competitive pressures. The 19.8% upside to consensus price target of $272.43 presents opportunity, though investors should monitor Q3 2026 earnings results on October 22 for margin trajectory confirmation amid bearish technical indicators.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Packaging Corporation of America
Packaging Corporation of America is a leading producer of containerboard and corrugated packaging products in North America. The company also produces white papers, which include printing and writing papers. PKG operates as an integrated manufacturer, with a strong focus on high-quality and sustainable packaging solutions for e-commerce, food and beverage, and other industrial and consumer markets.
Read more on PKG →
